Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Total Liabilities
Everything the company owes to creditors and other parties.
Arbutus Biopharma CorporationNASDAQ: ABUS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 55.1% from a year ago
Total liabilities stood at $16.99M at the end of Q1 FY2026, down 55.1% from a year earlier and down 5.8% from the prior quarter. Over 3 fiscal years it compounded at -32.5% a year.
Context
- Total liabilities amounted to 6.1% of total assets at the end of Q1 FY2026, down 26.2 pp from a year earlier.
- Total liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -55.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 18.04M USD
- Year-over-year change
- -47.5%
- 4-year CAGR
- -15.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.04M | -47.5% |
| FY2024 | 2024-12-31 | 34.34M | -10.5% |
| FY2023 | 2023-12-31 | 38.38M | -34.5% |
| FY2022 | 2022-12-31 | 58.57M | +67.1% |
| FY2021 | 2021-12-31 | 35.05M | — |
Total Liabilities vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's Mar 2026 total liabilities of $16.99M is the 8th highest of the 9 companies compared; the peer median is $131.92M.
- Its year-over-year change of -55.1% is the 8th highest of 9, against a peer median of -16.5%.
- Total liabilities amounts to 6.1% of total assets for ABUS, versus a peer median of 38.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.2B | -2.6% | +4.1% | 75.6% | |
| Sep 2026 | $1.69B | +91.4% | +52.2% | 97.1% | |
| Mar 2026 | $212.82M | -19.4% | -31.0% | 20.8% | |
| Mar 2026 | $198.12M | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $65.72M | -77.9% | -6.8% | 57.1% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.37M | +15.5% | +15.0% | 12.5% | |
| Mar 2026 | $16.99M | -55.1% | -32.5% | 6.1% | |
| Mar 2026 | $3.67M | -52.0% | -9.4% | 2.0% | |
| Peer median (excluding ABUS) | $131.92M | -16.5% | +9.6% | 38.9% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 109.28M | 30.78M | 26.29M | 36.33M | 18.01M |
| Short-term Investments | 46.04M | 116.14M | 99.72M | 86.29M | 73.46M |
| Net Receivables | 899K | 1.35M | 1.78M | 2.41M | 1.75M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.87M | 4.25M | 2.28M | 1.24M |
| Total Current Assets | 160.66M | 151.14M | 132.03M | 127.32M | 94.46M |
| Property, Plant & Equipment (Net) | 8.07M | 6.81M | 6.09M | 4.36M | 32K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 35.69M | 37.36M | 6.28M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 61K | 103K | 0 | 34K | 130K |
| Total Non-current Assets | 43.82M | 44.28M | 12.37M | 4.39M | 162K |
| Total Assets | 204.49M | 195.42M | 144.4M | 131.71M | 94.62M |
| Account Payables | 3.17M | 3.52M | 3.22M | 2.32M | 1.17M |
| Short-term Debt | 383K | 372K | 0 | 0 | 547K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 16.46M | 11.79M | 7.57M | 0 |
| Other Current Liabilities | 3.39M | 8.78M | 3.7M | 0 | 2.13M |
| Total Current Liabilities | 11.22M | 32.86M | 22.49M | 15.62M | 6.01M |
| Long-term Debt | 16.3M | 10.37M | 6.95M | 4.83M | 3.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 6M | 0 | 2.86M | 0 |
| Other Non-current Liabilities | 5.3M | 7.53M | 7.6M | 10.23M | 8.4M |
| Total Non-current Liabilities | 23.83M | 25.71M | 15.9M | 18.72M | 12.04M |
| Total Liabilities | 35.05M | 58.57M | 38.38M | 34.34M | 18.04M |
| Common Stock | 1.29B | 1.32B | 1.35B | 1.41B | 1.42B |
| Retained Earnings | (1.13B) | (1.2B) | (1.28B) | (1.35B) | (1.38B) |
| Accumulated OCI | (48.33M) | (50.49M) | (48.42M) | (48.14M) | (48.1M) |
| Other Stockholders Equity | (1) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 169.44M | 136.85M | 106.02M | 97.37M | 76.58M |
| Total Debt | 18.91M | 12.55M | 8.72M | 6.12M | 4.19M |
| Net Debt | (90.37M) | (18.22M) | (17.56M) | (30.21M) | (13.82M) |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.